284 related articles for article (PubMed ID: 16322102)
1. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.
Austin CD; Wen X; Gazzard L; Nelson C; Scheller RH; Scales SJ
Proc Natl Acad Sci U S A; 2005 Dec; 102(50):17987-92. PubMed ID: 16322102
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.
Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13872-7. PubMed ID: 16950881
[TBL] [Abstract][Full Text] [Related]
3. Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate.
Scales SJ; Tsai SP; Zacharias N; Cruz-Chuh JD; Bullen G; Velasquez E; Chang J; Bruguera E; Kozak KR; Sadowsky J
Bioconjug Chem; 2019 Dec; 30(12):3046-3056. PubMed ID: 31726009
[TBL] [Abstract][Full Text] [Related]
4. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
5. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.
Austin CD; De Mazière AM; Pisacane PI; van Dijk SM; Eigenbrot C; Sliwkowski MX; Klumperman J; Scheller RH
Mol Biol Cell; 2004 Dec; 15(12):5268-82. PubMed ID: 15385631
[TBL] [Abstract][Full Text] [Related]
6. Reduction of disulfide bonds within lysosomes is a key step in antigen processing.
Collins DS; Unanue ER; Harding CV
J Immunol; 1991 Dec; 147(12):4054-9. PubMed ID: 1721638
[TBL] [Abstract][Full Text] [Related]
7. Cell killing by antibody-drug conjugates.
Kovtun YV; Goldmacher VS
Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
[TBL] [Abstract][Full Text] [Related]
8. Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.
Klussman K; Mixan BJ; Cerveny CG; Meyer DL; Senter PD; Wahl AF
Bioconjug Chem; 2004; 15(4):765-73. PubMed ID: 15264863
[TBL] [Abstract][Full Text] [Related]
9. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.
Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
J Pharmacol Exp Ther; 2007 May; 321(2):462-8. PubMed ID: 17289839
[TBL] [Abstract][Full Text] [Related]
11. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
12. LIM kinase 1: evidence for a role in the regulation of intracellular vesicle trafficking of lysosomes and endosomes in human breast cancer cells.
Nishimura Y; Yoshioka K; Bernard O; Himeno M; Itoh K
Eur J Cell Biol; 2004 Aug; 83(7):369-80. PubMed ID: 15503860
[TBL] [Abstract][Full Text] [Related]
13. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.
Miyano T; Wijagkanalan W; Kawakami S; Yamashita F; Hashida M
Mol Pharm; 2010 Aug; 7(4):1318-27. PubMed ID: 20527783
[TBL] [Abstract][Full Text] [Related]
14. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
[TBL] [Abstract][Full Text] [Related]
15. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.
Harper J; Mao S; Strout P; Kamal A
Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140
[TBL] [Abstract][Full Text] [Related]
16. Transport of residual endocytosed products into terminal lysosomes occurs slowly in rat liver endothelial cells.
Hellevik T; Martinez I; Olsen R; Toh BH; Webster P; Smedsrød B
Hepatology; 1998 Nov; 28(5):1378-89. PubMed ID: 9794925
[TBL] [Abstract][Full Text] [Related]
17. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
Burke PJ; Toki BE; Meyer DW; Miyamoto JB; Kissler KM; Anderson M; Senter PD; Jeffrey SC
Bioorg Med Chem Lett; 2009 May; 19(10):2650-3. PubMed ID: 19386499
[TBL] [Abstract][Full Text] [Related]
18. Gene silencing reveals a specific function of hVps34 phosphatidylinositol 3-kinase in late versus early endosomes.
Johnson EE; Overmeyer JH; Gunning WT; Maltese WA
J Cell Sci; 2006 Apr; 119(Pt 7):1219-32. PubMed ID: 16522686
[TBL] [Abstract][Full Text] [Related]
19. Reduction-sensitive liposomes from a multifunctional lipid conjugate and natural phospholipids: reduction and release kinetics and cellular uptake.
Goldenbogen B; Brodersen N; Gramatica A; Loew M; Liebscher J; Herrmann A; Egger H; Budde B; Arbuzova A
Langmuir; 2011 Sep; 27(17):10820-9. PubMed ID: 21819046
[TBL] [Abstract][Full Text] [Related]
20. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
